Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to Integrin Integrin alpha 5 beta 1. Volociximab (also known as M200) is a chimeric monoclonal antibody jointly for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin. It is thought to reduce metastases. Early results show potential in renal cell cancers.
Target
Integrin alpha 5 beta 1
Type
IgG4
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in IP, IF, FuncS, FC, Neut, ELISA, ICC and most other immunological methods.
CAS
558480-40-3
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G4, anti-(human a5b1 integrin) (human-mouse clone p200-M heavy chain), disulfide with human-mouse clone p200-M k-chain, dimer
Predicted N terminal
H Chain: MAVLGLL; L Chain: MDFQVQV
Molecular Weight
145500
Purity
>95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
Size
1mg
Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
BACKGROUND
Antigen Description
This protein belongs to the integrin alpha chain family. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This gene encodes the integrin alpha V chain. Alpha chain V undergoes post-translational cleavage in the extracellular domain to yield disulfide-linked light and heavy chains that join with beta 1 to form a fibronectin receptor. In addition to adhesion, integrins are known to participate in cell-surface mediated signalling.